Legend Biotech 

Yahoo Finance • 25 days ago

Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears

Key Points New York City-based Suvretta Capital Management increased its MLYS position by 387,641 shares in the third quarter. The overall position value increased by $57.25 million from the previous period. As of September 30, Suvretta r... Full story

Yahoo Finance • 26 days ago

Here is Why Legend Biotech (LEGN) Offers Such Promising Upside

Legend Biotech (NASDAQ:LEGN) is one of the most promising mid-cap healthcare stocks under $50. As of December 19 closing, the consensus ratings for Legend Biotech (NASDAQ:LEGN) remain bullish. After a drop of almost 33% during 2025, the s... Full story

Yahoo Finance • last month

Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

Legend Biotech USA Inc. SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive O... Full story

Yahoo Finance • last month

Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects

Legend Biotech Corp (NASDAQ:LEGN) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, RBC Capital reiterated an Outperform rating on Legend Biotech Corp (NASDAQ:LEGN) and set a $74 price target.Legend... Full story

Yahoo Finance • last month

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI® Translational analyses show stronger immune fitness and a more immunoc... Full story

Yahoo Finance • 2 months ago

Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade

Recognizes the company’s continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, reinforcing Flanders’ position as a global biotech hub SOMERSET, N.J. and GHENT, Belgium, Nov. 27, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 2 months ago

William Blair Maintains Hold Rating on Legend Biotech (LEGN) Despite Carvykti Label Safety Concerns

Legend Biotech Corporation (NASDAQ:LEGN) ranks among the most oversold biotech stocks to invest in. On November 12, William Blair analyst Sami Corwin reiterated his Hold rating for Legend Biotech Corporation (NASDAQ:LEGN) shares. The analy... Full story

Yahoo Finance • 2 months ago

Oversold Conditions For Legend Biotech (LEGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 2 months ago

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

31,000-square-foot site expands Legend’s U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation The facility will support CAR-T R&D in potential oncology and immunology indications A Media Snippet a... Full story

Yahoo Finance • 3 months ago

SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress

DUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)... Full story

Yahoo Finance • 3 months ago

Legend Biotech, J&J ink Carvykti supply agreement

[Janssen Pharmaceuticals office in Brisbane, California, USA] JHVEPhoto/iStock Editorial via Getty Images * Legend Biotech (NASDAQ:LEGN [https://seekingalpha.com/symbol/LEGN]) and Johnson & Johnson's (NYSE:JNJ [https://seekingalpha.com/... Full story

Yahoo Finance • 4 months ago

Sector Update: Health Care Stocks Rise Friday Afternoon

Health care stocks advanced Friday afternoon, with the NYSE Health Care Index up 0.2% and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 5 months ago

The Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma Expertise

On August 18, 2025, Legend Biotech appointed Carlos Santos as Chief Financial Officer and principal accounting officer, succeeding interim CFO Jessie Yeung, bringing decades of finance leadership from AstraZeneca, Novartis, and Intel to th... Full story

Yahoo Finance • 5 months ago

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

Legend Biotech USA Inc. SOMERSET, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive O... Full story

Yahoo Finance • 5 months ago

Legend Biotech appoints Carlos Santos as CFO

[concept word CFO on cubes.close up of wooden elements,Business Concept.3D rendering on blue background.] Legend Biotech (NASDAQ:LEGN [https://seekingalpha.com/symbol/LEGN]) has appointed [https://seekingalpha.com/pr/20203488-legend-biote... Full story

Yahoo Finance • 5 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

SOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company’s Chief Financial Officer, eff... Full story

Yahoo Finance • 5 months ago

Germany stocks higher at close of trade; DAX up 0.75%

Investing.com – Germany stocks were higher after the close on Thursday, as gains in the Financial Services, Food & Beverages and Industrials sectors led shares higher. At the close in Frankfurt, the DAX added 0.75% to hit a new 1-month hi... Full story

Yahoo Finance • 5 months ago

Legend Biotech Corp (LEGN) Q2 2025 Earnings Call Highlights: Record CARVYKTI Sales and ...

CARVYKTI Net Trade Sales: $439 million, a 136% increase year over year. Total Revenues: $255 million, driven by collaboration revenue growth of 136% year over year. Net Loss: $125 million, with an adjusted net income of $10 million after e... Full story

Yahoo Finance • 5 months ago

Legend Bio earnings missed by $0.22, revenue topped estimates

Investing.com - Legend Bio (NASDAQ: LEGN) reported second quarter EPS of $-0.34, $0.22 worse than the analyst estimate of $-0.12. Revenue for the quarter came in at $255.06M versus the consensus estimate of $234.23M. Legend Bio’s stock pr... Full story

Yahoo Finance • 5 months ago

Legend Biotech Corp. (NASDAQ:LEGN) Reports Mixed Q2 2025 Earnings with Revenue Beat and EPS Miss Amid Strong CARVYKTI Sales

LEGEND BIOTECH CORP. (NASDAQ:LEGN [https://www.chartmill.com/stock/quote/LEGN]) REPORTS Q2 2025 EARNINGS: REVENUE BEATS, EPS MISSES AMID STRONG CARVYKTI SALES Legend Biotech Corp. released its second-quarter 2025 financial results, delive... Full story